TABLE 1.

Protection against experimental infection with T. solium cysticerci by vaccination with the TSOL18 and/or TSOL45-1A recombinant oncosphere antigen^a

Trial and vaccine	Trial location	T. solium cysticerci in pigs		Mean % cysticercus viability (range) at time of necropsy	Mean protection (%)c
		No. in individual animalsb	Mean
1	Mexico
GST		167, 206, 234, 262, 415	256.8	40 (0.4-100)
TSOL18		0, 0, 0, 0, 0	0		100d
TSOL45-1A		28, 51, 151, 193, 258	136.2	72 (11-99)	0
TSOL18+45		0, 0, 3, 9, 56	13.6	30 (22-100)	94.7d
2	Mexico
GST or none		6, 10, 11, 13, 17, 26, 28, 40, 59, 64, 100, 127	41.8	17 (0-51)
TSOL18		0, 0, 0, 0, 1	0.2	0	99.5d
TSOL45-1A		0, 0, 0, 0, 6	1.2	0	97.1d
3	Cameroon
None		0, 4, 18, 39, 89	30.0	11 (0-94)
TSOL18		0, 0, 0, 0, 0	0	0	100e

^aPigs received intramuscular immunizations with the recombinant antigen(s) together with 1 mg of Quil A adjuvant prior to challenge infection with viable eggs of T. solium, and necropies were performed approximately 3 months after the challenge infection.

^bFor trials 2 and 3, the entire body musculature was assessed; for trial 1, the numbers of cysticerci in the right hind leg, heart, tongue, were and diaphragm assessed.

^cProtection was calculated as the percent reduction in the mean number of cysticerci in each group in comparison with the mean number of cysticerci in the control group of the same experiment and is shown only for those groups for which the difference was statistically significant.

^dP < 0.01 versus control group.

^eP < 0.05 versus control group.